Abivax receives FDA feedback with guidance on advancing ABX464 into phase 3 clinical testing in ulcerative colitis

Abivax SA , a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, today announced that... | December 1, 2021

Related Keywords

Japan ,United States ,Paris ,France General ,France ,America ,Hartmutj Ehrlich , ,European Medicines Agency ,Drug Administration ,Euronext ,Euronext Paris ,North America ,Abivax Stock Exchange ,News ,Information ,Press Release ,Abivax ,Biotechnology ,Company ,Developing ,Novel ,Therapies ,Hat ,Modulate ,The ,Immune ,System ,O ,Treat ,Hronic ,Inflammatory ,Viral ,End ,Oday ,Nnounced Abvx Fr0012333284 ,